AdjuTec Pharma’s CEO to BioStock: “Our goal is to set a new standard in antibiotic treatment”
Late last year, AdjuTec Pharma launched a phase I clinical trial for its lead candidate, APC148, targeting antimicrobial resistance, AMR. Recently, seasoned life science executive Jethro Holter stepped into the CEO role. BioStock talked with Holter to discuss his decision to join AdjuTec Pharma, exploring his vision for the company and the role APC148 could play in tackling the global AMR challenge.
Read the full interview with Jethro Holter at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/